康泰生物：2024年公司免疫规划疫苗收入为6108.36万元，仅占当期营业收入的2.3%

Core Viewpoint - The company, Kangtai Biological (300601), has indicated that its revenue from immunization program vaccines has historically been relatively low compared to its overall revenue, with a specific focus on the distinction between immunization program vaccines and non-immunization program vaccines [1] Group 1: Revenue Breakdown - The company's revenue from immunization program vaccines for the year 2024 is reported to be 61.08 million yuan, which constitutes only 2.3% of the total operating revenue for that period [1]